Hycult Biotech Inc. names Executive Director to Board

PLYMOUTH MEETING, Pa- January 06, 2011. Hycult Biotech Inc., a wholly owned Subsidiary of Hycult Biotech B.V., a provider of innovative immunology and cell biology solutions, has named Mr. Dino DiCamillo as Executive Director, of its newly incorporated U.S. Subsidiary. 
“As a business leader and industry expert, Mr. DiCamillo brings to Hycult Biotech Inc. a deep understanding of operations necessary to support a local subsidiary”
.Mr. DiCamillo brings extensive expertise and experience in the areas of immunology, genomics, proteomics, and business operations and management. He currently serves as President and CEO of Percorso Life Sciences, where he partners with early stage technology companies and provides direction and leadership to companies looking to establish a U.S. presence. More recently, Mr. DiCamillo served as Vice President and Officer of Advanced Research Technologies, President of Alfa Wassermann Proteomics, Vice President of Environmental Diagnostics at Invitrogen, and President of Dynal Biotech Inc, where he provided strategic leadership and execution in a variety of roles.
"As a business leader and industry expert, Mr. DiCamillo brings to Hycult Biotech Inc. a deep understanding of operations necessary to support a local subsidiary," said Mr. Rik van Heijningen, Managing Director of Hycult Biotech B.V. "His expertise with new technology adoption, operations, and channel management will assist Hycult Biotech Inc. execute its local strategy." 
"I am proud to play a role in the development and execution of Hycult’s local strategy,” said Mr. DiCamillo. "Hycult Biotech offers a broad and unique technology specific to researchers who focus on the innate immune system, which facilitates the understanding of the immune system paradigm."

Hycult Biotech b.v. Announces Formation of Hycult Biotech Inc. to Serve the Innate Immune Market Segment in the Americas
Uden, The Netherlands, December 1, 2010 – Hycult Biotechnology bv (Hycult Biotech) announced today the formation of Hycult Biotech Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. The Company specializes in the development, manufacturing and commercialization of antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields.  Read more

Hycult Biotech announces establishment of Scientific Advisory Board
23 of August, 2010 -Uden, The Netherlands. -Hycult Biotechnology BV (Hycult Biotech), a biotechnology company and a leader in the development of innovative and new Innate Immunity Life Sciences reagents announces the establishment of its Scientific Advisory Board (SAB). The SAB will further guide the Company in its scientific development and focus within the field of Innate Immunity. Read more

Cardiff University and Hycult Biotech entering an exclusive deal for factor H variant assay (April 2009)
Hycult Biotech (HB) has obtained the exclusive rights from Cardiff University for the development of a factor H variant (Y402/H402) research assay. This unique tool is developed in close collaboration between Prof. Paul Morgan (dept. Medical Biochemistry and Immunology) at Cardiff University and the R&D department of HB and is developed within 5 months after signing the agreement.  Read more
If you as scientist are interested in a collaboration or commercialization of any of your reagents please contact Loek Willems at: l.willems@hycultbiotech.com